A Phase Ib Study of the Effects of Black Raspberries on Rectal Polyps in Patients With Familial Adenomatous Polyposis | oneFAPvoice

welcome to oneFAPvoice

- a positively charged Familial Adenomatous Polyposis community.
  • join today!
scientific articles

A Phase Ib Study of the Effects of Black Raspberries on Rectal Polyps in Patients With Familial Adenomatous Polyposis

key information

source: Cancer prevention research

year: 2014

authors: Wang L S, Burke C A, Hasson H, Kuo C T, Molmenti C L, Seguin C, Liu P, Huang T H, Frankel W L, Stoner G D

summary/abstract:

Familial adenomatous polyposis (FAP) is characterized by the early onset of colonic polyposis and a high risk for colorectal cancer. FAP is treated by colectomy followed by lifelong removal of rectal polyps. This study determined whether black raspberries (BRBs) might regress rectal polyps in patients with FAP. Fourteen patients with FAP were treated with BRBs daily for 9 months. Seven patients received BRB powder orally plus two BRB suppositories inserted into the rectum at bedtime. The other 7 received an oral placebo plus the suppositories. Rectal polyp counts and polyp sizes were obtained at time zero and after 9 months of BRB treatment. Polyps and adjacent normal tissue were collected at both time points. The burden (P = 0.036) but not number (P = 0.069) of rectal polyps was significantly decreased. No benefit was noted with the addition of oral BRBs. Three patients were nonresponders. BRBs significantly decreased cellular proliferation, DNA methylation methyl transferase 1 protein expression, and p16 promoter methylation, but not promoter methylation of the Wnt pathway antagonists, SFRP2 and WIF1, in rectal polyps (adenomas) from responders but not from nonresponders. The MBD-seq assay revealed more demethylated transcription start sites (TSS), including those for miRNAs, in BRB-treated adenomas from the responders. In conclusion, BRB suppositories seem sufficient for regressing rectal polyps in patients with FAP.

©2014 American Association for Cancer Research.

organisation: Cleveland Clinic, Columbia University, Comprehensive Cancer Center, Medical College of Wisconsin, University of Texas, Ohio State University

DOI: 10.1158/1940-6207.CAPR-14-0052

abstract source full text source